"Managing type 2 diabetes can be challenging
The role of NRF2 in oncogenesis is intricate [68]
This session is all about getting to know you, so dont hold back on sharing details that might seem minor
So, we wanted to take a moment to let you know the truth about this drug
It has also shown promise in cardiac tissue repair and neuroprotection
Tschop recounted his research with DiMarchi and that of others while he accepted the 2023 Banting Medal for Scientific Achievement at the 2023 American Diabetes Association Scientific Sessions.5 The FDA approved the first GLP-1 agonist, twice-a-day Byetta (exenatide), in 2005.1 Since then, several newer and more powerful medications in the GLP-1 agonist class, such as liraglutide and semaglutide, have received FDA approval for type 2 diabetes, with a higher dose of semaglutide FDA approved for weight loss.2 In mid-2022, the first dual agonist, tirzepetide (a combination of a GLP-1 agonist and a GIP), was FDA approved for type 2 diabetes